Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
The recent approval of omaveloxolone for the treatment of Friedreich ataxia in the USA and Europe represents an important milestone in the field of rare neurological diseases. However, many challenges lie ahead, including the translation of trial results into clinical practice, and the management of patients’ expectations.
Various neurostimulation techniques are being explored for the treatment of physical impairments in people with stroke. This Review summarizes our current knowledge of the techniques that are now in clinical use or have reached the stage of pivotal trials alongside emerging techniques and highlights the need for further studies.
Post-traumatic epilepsy is a major driver of disability associated with traumatic brain injury. This article reviews the epidemiology and clinical features of post-traumatic epilepsy and discusses how an understanding of the underlying epileptogenic mechanisms might inform the development of anti-epileptogenic medications.
In this Review, the authors discuss the unique neurological health disparities faced by sexual and gender minority (LGBT+) people. The Review presents clinical considerations alongside language and practice recommendations to promote inclusive care, and highlights the gaps in need of further research.
Since its instigation in cancer research in the 1930s, the disease-staging concept has become a crucial tool in clinical research and medical practice. Two new papers have proposed biological staging and classification systems based on α-synuclein pathology for Parkinson disease and related conditions.
A new study has found evidence of α-synuclein aggregates — a key pathological hallmark of Parkinson disease — in the gut and brain in people and animals with inflammatory bowel disease.
Recent clinical trials have highlighted the need for Alzheimer disease (AD) staging rather than simply noting the presence or absence of AD pathology. This article reviews current biomarker-based AD staging systems and outlines hypothetical frameworks to stage AD severity using fluid biomarkers.
Alzheimer disease is a complex and multifactorial condition. The authors of this Perspective suggest that its lack of a singular common pathogenesis prevents it from being regarded as a straightforward ‘disease’ and that treatment will therefore require a multifaceted approach.
In this Review, Hamilton dissects the importance of racial and ethnic diversity among the neurology workforce for providing inclusive and equitable care to diverse populations. The Review summarizes current barriers to achieving diversity in the field and presents strategic approaches to overcoming these.
Success in a trial of low-intensity ultrasound combined with an amyloid-β antibody represents a major stride towards integrating pharmacological and nonpharmacological approaches to reduce the amyloid-β load in patients with mild Alzheimer disease. This trial also highlights the potential of therapeutic ultrasound modalities to combat neurodegenerative diseases.
Growing evidence suggests a bidirectional relationship between Alzheimer disease and epilepsy. This Review summarizes the epidemiological evidence and explores the potential mechanisms that underlie the effects of epileptiform activity on cognition in people with Alzheimer disease.
T cells that are specific for B cells infected with Epstein–Barr virus are enriched in the cerebrospinal fluid of people with early multiple sclerosis, according to new research.
